EHA Library - The official digital education library of European Hematology Association (EHA)

IMPROVE RISK-STRATIFICATION OF MULTIPLE MYELOMA PATIENT WITH MICROFLUIDIC DEVICES
Author(s):
Calvin Li
,
Calvin Li
Affiliations:
University of Southern California,Los Angeles,United States
Li Gao
,
Li Gao
Affiliations:
University of Southern California,Los Angeles,United States
Yunjing Zeng
,
Yunjing Zeng
Affiliations:
University of Southern California,Los Angeles,United States
Xi Zhang
,
Xi Zhang
Affiliations:
University of Southern California,Los Angeles,United States
John Zhong
John Zhong
Affiliations:
University of Southern California,Los Angeles,United States
(Abstract release date: 05/18/17) EHA Library. Zhong J. 05/18/17; 182655; PB1941
John Zhong
John Zhong
Contributions
PDF Abstract
Abstract

Abstract: PB1941

Type: Publication Only

Background

Cytogenetic alterations are required for risk stratification of multiple myeloma (MM); however, current pathology assays performed on bone marrow samples directly can produce false negatives due to the unpredictable distribution and rarity of MM cells. A more accurate method is needed for MM diagnosis and risk-stratification. We develop a new microfluidic device to facilitate CD45-depletion for enhancing the detection of cytogenetic alterations in plasma cells.

Aims
Improve accuracy of risk stratification for multiple myeloma patients

Methods

Bone marrow samples from 48 MM patients were divided into two parts each. One part was directly detected by classic flow cytometry and FISH while the other part was first enriched by microfluidic size selection and then underwent CD45-cell depletion (MF-CD45-TACs). The enriched samples were then analyzed by flow cytometry and FISH and compared to the classical analysis.

Results

MF-CD45-TACs significantly increased the percentage of CD38+/CD138+ cells to 37.7%±20.4% (P<0.001) compared to 10.3%±8.5% in bone marrow. After the MF-CD45-TACs enrichment, the detection rate of IgH rearrangement, del(13q14), del(17p) and 1q21 gains rose to 56.3%(P<0.001), 37.5%(P<0.001), 22.9%(P<0.001) and 41.7% (P=0.001), respectively, all significant increases compared to untreated samples.

Conclusion
We have developed a rapid, simple assay for improved diagnostics and risk-stratification for MM. With more precise diagnosis, the clinical outcomes of MM will be significantly improved.

Session topic: 13. Myeloma and other monoclonal gammopathies - Biology

Keyword(s): Multiple Myeloma

Abstract: PB1941

Type: Publication Only

Background

Cytogenetic alterations are required for risk stratification of multiple myeloma (MM); however, current pathology assays performed on bone marrow samples directly can produce false negatives due to the unpredictable distribution and rarity of MM cells. A more accurate method is needed for MM diagnosis and risk-stratification. We develop a new microfluidic device to facilitate CD45-depletion for enhancing the detection of cytogenetic alterations in plasma cells.

Aims
Improve accuracy of risk stratification for multiple myeloma patients

Methods

Bone marrow samples from 48 MM patients were divided into two parts each. One part was directly detected by classic flow cytometry and FISH while the other part was first enriched by microfluidic size selection and then underwent CD45-cell depletion (MF-CD45-TACs). The enriched samples were then analyzed by flow cytometry and FISH and compared to the classical analysis.

Results

MF-CD45-TACs significantly increased the percentage of CD38+/CD138+ cells to 37.7%±20.4% (P<0.001) compared to 10.3%±8.5% in bone marrow. After the MF-CD45-TACs enrichment, the detection rate of IgH rearrangement, del(13q14), del(17p) and 1q21 gains rose to 56.3%(P<0.001), 37.5%(P<0.001), 22.9%(P<0.001) and 41.7% (P=0.001), respectively, all significant increases compared to untreated samples.

Conclusion
We have developed a rapid, simple assay for improved diagnostics and risk-stratification for MM. With more precise diagnosis, the clinical outcomes of MM will be significantly improved.

Session topic: 13. Myeloma and other monoclonal gammopathies - Biology

Keyword(s): Multiple Myeloma

Premium Sponsors

What's new at EHA

Browse the open-source material from EHA past Congresses and meetings.

References

EHA Terms & Conditions
2025 ©
European Hematology Association
USER TERMS AND CONDITIONS / PRIVACY POLICY
(Amended according to GDPR)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies